Brokerages Set Becton, Dickinson and Company (NYSE:BDX) Target Price at $181.00

Becton, Dickinson and Company (NYSE:BDX) has earned an average rating of “Hold” from the sixteen ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $181.00.

BDX has been the subject of several analyst reports. Barclays raised their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Evercore raised their target price on Becton, Dickinson and Company from $180.00 to $190.00 in a research report on Thursday, May 7th. Argus cut their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research report on Monday, March 23rd. Piper Sandler cut their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Finally, Wells Fargo & Company raised their target price on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th.

Becton, Dickinson and Company Trading Up 0.0%

Shares of BDX opened at $143.99 on Wednesday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $39.67 billion, a price-to-earnings ratio of 36.45, a P/E/G ratio of 10.19 and a beta of 0.22. The stock’s 50-day moving average price is $148.89 and its 200 day moving average price is $172.17.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same period in the previous year, the company posted $3.35 earnings per share. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Insider Activity at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $16,122,355.05. This represents a 2.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total value of $166,628.00. Following the sale, the executive vice president owned 14,272 shares in the company, valued at approximately $2,161,922.56. This trade represents a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,013 shares of company stock valued at $593,434 in the last 90 days. 0.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

Large investors have recently bought and sold shares of the business. Brighton Jones LLC raised its stake in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares during the period. Vanguard Group Inc. raised its stake in Becton, Dickinson and Company by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock worth $6,074,750,000 after buying an additional 147,041 shares during the period. Graybill Wealth Management LTD. raised its stake in Becton, Dickinson and Company by 47.3% during the 3rd quarter. Graybill Wealth Management LTD. now owns 27,592 shares of the medical instruments supplier’s stock worth $5,164,000 after buying an additional 8,859 shares during the period. Skba Capital Management LLC raised its stake in Becton, Dickinson and Company by 1,619.9% during the 3rd quarter. Skba Capital Management LLC now owns 57,514 shares of the medical instruments supplier’s stock worth $10,765,000 after buying an additional 54,170 shares during the period. Finally, Danske Bank A S acquired a new stake in Becton, Dickinson and Company during the 3rd quarter worth $34,596,000. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.